Correlation Between Golden Biotechnology and GeneFerm Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Golden Biotechnology and GeneFerm Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Golden Biotechnology and GeneFerm Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Golden Biotechnology and GeneFerm Biotechnology Co, you can compare the effects of market volatilities on Golden Biotechnology and GeneFerm Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Golden Biotechnology with a short position of GeneFerm Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Golden Biotechnology and GeneFerm Biotechnology.

Diversification Opportunities for Golden Biotechnology and GeneFerm Biotechnology

-0.27
  Correlation Coefficient

Very good diversification

The 3 months correlation between Golden and GeneFerm is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding Golden Biotechnology and GeneFerm Biotechnology Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GeneFerm Biotechnology and Golden Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Golden Biotechnology are associated (or correlated) with GeneFerm Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GeneFerm Biotechnology has no effect on the direction of Golden Biotechnology i.e., Golden Biotechnology and GeneFerm Biotechnology go up and down completely randomly.

Pair Corralation between Golden Biotechnology and GeneFerm Biotechnology

Assuming the 90 days trading horizon Golden Biotechnology is expected to under-perform the GeneFerm Biotechnology. In addition to that, Golden Biotechnology is 1.39 times more volatile than GeneFerm Biotechnology Co. It trades about -0.12 of its total potential returns per unit of risk. GeneFerm Biotechnology Co is currently generating about 0.03 per unit of volatility. If you would invest  4,600  in GeneFerm Biotechnology Co on September 24, 2024 and sell it today you would earn a total of  120.00  from holding GeneFerm Biotechnology Co or generate 2.61% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Golden Biotechnology  vs.  GeneFerm Biotechnology Co

 Performance 
       Timeline  
Golden Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Golden Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
GeneFerm Biotechnology 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in GeneFerm Biotechnology Co are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, GeneFerm Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Golden Biotechnology and GeneFerm Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Golden Biotechnology and GeneFerm Biotechnology

The main advantage of trading using opposite Golden Biotechnology and GeneFerm Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Golden Biotechnology position performs unexpectedly, GeneFerm Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneFerm Biotechnology will offset losses from the drop in GeneFerm Biotechnology's long position.
The idea behind Golden Biotechnology and GeneFerm Biotechnology Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bonds Directory
Find actively traded corporate debentures issued by US companies